Dr Reddy's to buy Russian drug portfolio; Glenmark to ramp up on Salix HIV drug;

  @FiercePharma: Merck amps up in China with Simcere JV. Report | Follow @FiercePharma

> India's Dr Reddy's Laboratories agreed to buy JB Chemicals & Pharmaceuticals' drug prescription portfolio in Russia and several other countries in an approximately $34.9 million deal. Report

> Salix Pharmaceuticals has updated its supply agreement with India's Glenmark Pharmaceuticals to increase manufacturing of its HIV-associated diarrhea drug, Crofelemer. Article

> According to results from a Japanese study, Bayer's Xarelto blood thinner wasn't associated with a higher risk of bleeding for irregular-heartbeat patients compared to the previous standard of care, warfarin. Item

> GlaxoSmithKline sued Watson Pharmaceuticals to protect the patent on its prostate drug Jalyn, which Watson is seeking FDA permission to copy. News

> Victory Pharma, a specialty pharmaceutical company with operations in Cary, NC, and San Diego, will eliminate 179 positions when the sale of its assets to Shionogi wraps up. Report

> Valeant Pharmaceuticals got Canadian approval for its sleep drug Sublinox, to be marketed in a joint venture with Meda. Release

> Sanofi said it has appointed Greg Irace to the role of senior vice president, global services; he is currently CEO of Sanofi's U.S. operations. Report

Biotech News

@FierceBiotech: Bristol-Myers snapping up Amira Pharma for $325M. Item | Follow @FierceBiotech

@JohnCFierce: Government pledging to overhaul rules on human research. From the NYT. Story | Follow @JohnCFierce

@RyanMFierce: John Halamka has a very lucid explanation for why Harvard Med School needs a full time CIO, NGS demands, storage, etc. Blog post | Follow @RyanMFierce

@MaureenFierce: FDA rejects new use for J&J immune disorder drug Simponi. News | Follow @MaureenFierce

> Government officials try to simplify the rules on human research. Article

> Analysis: Grim stats on CNS drugs demand fresh approach to development. Report

> Medicis inks $58M dermatology pact with India's Lupin. Piece

Biotech IT News

> Harvard Med School CIO Halamka exiting big job. Story

> Biomax Informatics expands deal with Royal DSM. More

> Mayo Clinic eyes future trial recruitment with health data exchanges. Report

> Bioinformatics upstart Intervention Insights secures $7.2M. Article

Medical Device News

> Nevro lands $58M for pain devices. More

> St. Jude to cut 450 Swedish Jobs. Release

> King's College spins out Centron Diagnostics. Story

> Imperial Innovations invests $6.5M in Stanmore Implants. Article

> Drew Medical's Dinkel banned from Medicare business. News

And Finally... Arthrosclerosis, which causes heart disease, can also result in dementia, researchers found. Report

Suggested Articles

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

Pfizer, GSK, BIO and others are all planning vaccine messages for fall.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.